Recent 8-K filings for TKNO
Highest-materiality recent filing
Alpha Teknova reports Q4 and FY2025 revenue growth, provides 2026 guidance of $42-44M
- Full year 2025 total revenue $40.5M, up 7% from $37.7M in 2024.
- Q4 2025 revenue $10.0M, up 8% from $9.3M in Q4 2024.
-
Teknova Q1 revenue $11.1M (+13% YoY); reaffirms FY 2026 guidance $42-44M
Total revenue $11.1M, up 13% YoY; Clinical Solutions revenue surged 85% to $2.1M.
-
Alpha Teknova reports Q4 and FY2025 revenue growth, provides 2026 guidance of $42-44M
Full year 2025 total revenue $40.5M, up 7% from $37.7M in 2024.
-
Teknova Q3 revenue $10.5M (+9% YoY); net loss narrows to $4.3M; reaffirms FY2025 guidance
Revenue $10.5M, up 9% from Q3 2024; Lab Essentials $8.3M (+16%), Clinical Solutions $1.7M (-13%).
-
Teknova Q2 revenue $10.3M (+7% YoY); net loss narrows to $3.6M; reaffirms FY25 guidance $39-42M
Q2 2025 revenue of $10.3M, up 7% from $9.6M in Q2 2024.
-
Alpha Teknova shareholders elect Demski and Herzick as Class I directors; auditor ratified
Martha J. Demski elected with 42,901,743 votes for (99.1% of votes cast, excluding broker non-votes).
-
Teknova Q1 revenue up 5% to $9.8M, net loss narrows to $4.6M, guidance reaffirmed
Q1 total revenue $9.8M (+5% YoY); Lab Essentials $8.1M (+12%), Clinical Solutions $1.2M (-32%).
-
Teknova reports FY2024 revenue $37.7M (+3% YoY), guides FY2025 $39-42M, amends credit facility
FY2024 revenue $37.7M (+3% YoY); Q4 revenue $9.3M (+18% YoY). Clinical Solutions Q4 revenue $1.85M (+110% YoY).
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.80 · Median 0.65 · Most common event earnings